AmpliPhi advances phage in clinic to address microbial infections
Using cocktails of bacteriophages to attack bacterial infections, San Diego-based AmpliPhi announced progress in Phase I studies of its lead program. Company CEO Scott Salka explains to Mike Ward, Informa Pharma Intelligence’s insights global director of content, how he is looking to secure sufficient capital to support the Phase II development of its lead program against chronic rhinosinusitis while advancing other candidate products.
Interviewer: Mike Ward – Global Director of Content, Informa Pharma Insights
Interviewee: Scott Salka – CEO, AmpliPhi BioSciences